Up­dat­ed: Small cannabi­noid biotech says its CMO was hit with cy­ber­at­tack, re­sult­ing in clin­i­cal tri­al de­lays

Ed­i­tor’s note: This ar­ti­cle has been up­dat­ed to in­clude com­ment from Punit Dhillon and in­for­ma­tion on Skye Bio­science’s merg­er with Emer­ald Health Ther­a­peu­tics, in­clud­ing fraud ac­cu­sa­tions against its chair­man, Av­tar Dhillon.

Skye Bio­science has de­layed a Phase I tri­al for its cannabi­noid glau­co­ma treat­ment due to an al­leged cy­ber­at­tack on its man­u­fac­tur­er.

The small San Diego biotech did not dis­close which con­tract man­u­fac­tur­er it us­es, but it did note the cy­ber­at­tack has since been re­solved. How­ev­er, due to the at­tack, the third-par­ty man­u­fac­tur­er had to de­lay its an­nu­al main­te­nance to Au­gust, ac­cord­ing to the com­pa­ny.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER